ZURICH, June 30 (Reuters) - A new Phase III study of Roche Holding AG's (ROG.VX: Quote, Profile, Research, Stock Buzz) cancer drug Avastin showed significantly improved survival in patients with metastatic colorectal cancer irrespective of K-Ras gene mutations, the Basel-based drug maker said on Monday.
